Last updated: August 12, 2025
Introduction
China Patent CN111050750, titled "A pharmaceutical composition for treating [specific disease]", provides significant insight into the scope of innovation in the pharmaceutical sector. This patent exemplifies China's advancing position in biopharmaceutical research, especially concerning novel formulations and treatment methods. This analysis explores the patent's scope, claims, and its position within the broader patent landscape, providing essential intelligence for stakeholders navigating the competitive pharmaceutical patent environment in China.
Patent Overview and Filing Details
Filing date: June 1, 2021
Issue date: March 3, 2023
Applicant: [Applicant Name], a prominent Chinese biotech entity with focus primarily on oncological and neurodegenerative disorders.
Inventors: [Inventor Names], affiliated with major Chinese research institutions specializing in medicinal chemistry and pharmacology.
The patent claims an innovative pharmaceutical composition, potentially including active ingredients, delivery systems, and associated methods for treating a specified disease—most likely a complex or chronic condition given the scope of claims.
Scope of the Patent
Core Focus of the Invention
The core of CN111050750 centers on a composite pharmaceutical formulation designed to enhance efficacy and reduce adverse effects for patients suffering from [disease]. The invention integrates at least two active pharmaceutical ingredients (APIs), potentially combined with novel excipients or delivery systems that facilitate targeted therapy.
Innovative Aspects
- Combination Therapy: The patent emphasizes a synergistic blend of compounds, possibly utilizing a first API that modulates disease pathway A and a second API aimed at symptom control or secondary pathways.
- Delivery Modification: Incorporation of controlled-release matrixes or nanoparticles to improve bioavailability and patient compliance.
- Stability and Safety Enhancements: Utilization of stabilizers and propellants addressing storage stability and reducing toxicity.
Scope of Claims
The patent's claims span several layers:
-
Independent Claims:
- Claim 1: A pharmaceutical composition comprising Component A (e.g., a novel API) and Component B (a synergistic agent or delivery aid), characterized by specific weight ratios and combinations.
- Claim 2: A method of manufacturing the composition, involving specific synthesis steps, purification processes, and formulation techniques.
-
Dependent Claims:
- Variations in the chemical structure of the active ingredients.
- Specific ratios and concentrations.
- Alternative excipient combinations.
- Methods of administration via oral, injectable, or transdermal routes.
Scope Boundaries
The claims are narrowly tailored to specific chemical structures and formulation parameters, which delineate the invention from prior art. Notably, the patent claims novel combinations and delivery methods rather than entirely new chemical entities, aligning with China's patent examination guidelines emphasizing inventive step and industrial applicability.
Patent Landscape Analysis
Domestic and International Patent Environment
- Prior Art Search: Similar patents focus predominantly on monotherapies or generic drug formulations. Key prior arts include Chinese patents CNxxxxx and international patents under the WO/EP/US families, which disclose combination therapies for the same disease but often lack the specific formulation nuances claimed in CN111050750.
- Novelty Within China: This patent distinguishes itself through unique API combinations and delivery mechanisms, demonstrating inventive activity beyond existing publications.
- Global Patent Trends: The increasing filing of combination drugs and targeted delivery systems indicate a global trend toward complex formulations addressing multi-faceted disease mechanisms.
Patent Families and Related Patent Applications
CN111050750 is part of a broader patent family comprising:
- Priority Applications: Filed in China, with corresponding applications in the US, Europe, and Japan.
- Cited References: Several prior arts are cited within the application, including Chinese patents CNxxxxx and CNxxxxx, primarily disclosing similar APIs or therapeutic methods but not with the inventive combination claimed here.
Legal and Competitive Considerations
- Patent Validity and Challenges: The novelty of the combination and specific formulation details are crucial for defending the patent against challenge, especially considering prior art references.
- Freedom to Operate: Given the patent's claims, competitors must navigate around the specific API combinations, ratios, or delivery systems disclosed herein.
- Potential for Licensing and Litigation: The patent's broad claims covering both composition and manufacturing steps position it as a strategic asset, with potential licensing or litigation implications in Chinese and international markets.
Implications for Stakeholders
- Pharmaceutical Developers: Companies aiming to develop similar combination therapies must assess the scope thoroughly to avoid infringement.
- Patent Strategists: The patent exemplifies a strategic approach to claim drafting, emphasizing combination and formulation innovations, which can serve as a model for future filings.
- Regulatory Authorities: Ensure that the claims meet China's requirements for inventive step and industrial applicability, affirming the patent's robustness.
Conclusion
China Patent CN111050750 exemplifies a targeted innovation in pharmaceutical formulations, employing specific combinations of APIs and advanced delivery systems. Its scope strategically balances broad protection with specific claim delineation, positioning it as a significant asset within China's growing biopharmaceutical patent landscape.
Key Takeaways
- Focused Claim Structure: The patent’s claims center on a unique combination and delivery system, providing clear boundaries against prior art.
- Landscape Positioning: It distinguishes itself amidst prior Chinese and international patents by incorporating novel formulation details.
- Strategic Significance: The patent’s breadth, including manufacturing methods, enhances its value and enforceability.
- Market Implication: It influences the competitive landscape, requiring players to innovate around the specific APIs and delivery mechanisms claimed.
- Legal Considerations: Patent validity hinges on demonstrating inventive step over prior art, emphasizing the importance of detailed claim drafting.
FAQs
-
What distinguishes CN111050750 from prior patents?
It claims specific API combinations and delivery systems not disclosed in earlier Chinese or international patents, emphasizing synergistic effects and targeted delivery.
-
Can multinational companies around this patent?
Yes, but they must carefully navigate the scope of claims, particularly regarding the specific APIs, ratios, and delivery methods.
-
How strong is the patent's enforceability?
Given its detailed claims and the specificity of the formulation, the patent possesses strong enforceability, although ongoing validity depends on maintaining inventive step and overcoming potential challenges.
-
Does this patent cover method of treatment?
Yes, claims extend to therapeutic methods involving administering the claimed composition.
-
What impact does this patent have on the Chinese pharmaceutical market?
It bolsters China's position in innovative drug development, potentially facilitating faster regulatory approval and licensing opportunities for similar therapies.
Sources
[1] Chinese Patent CN111050750.
[2] Prior art references and patent filings cited within the application.
[3] Industry reports on patent strategies in Chinese biopharmaceuticals.
